BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31582326)

  • 1. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma.
    Singal AK; Satapathy SK; Reau N; Wong R; Kuo YF
    Dig Liver Dis; 2020 Jan; 52(1):98-101. PubMed ID: 31582326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
    Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
    Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.
    Noureddin M; Vipani A; Bresee C; Todo T; Kim IK; Alkhouri N; Setiawan VW; Tran T; Ayoub WS; Lu SC; Klein AS; Sundaram V; Nissen NN
    Am J Gastroenterol; 2018 Nov; 113(11):1649-1659. PubMed ID: 29880964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Flemming JA; Kim WR; Brosgart CL; Terrault NA
    Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
    Young K; Liu B; Bhuket T; Gish RG; Wong RJ
    J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Holzner ML; Florman S; Schwartz ME; Tabrizian P
    HPB (Oxford); 2022 Apr; 24(4):470-477. PubMed ID: 34544629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of racial/ethnic and etiology/disease-specific factors is associated with lower survival following liver transplantation in African Americans: an analysis from UNOS/OPTN database.
    Wong RJ; Ahmed A
    Clin Transplant; 2014 Jul; 28(7):755-61. PubMed ID: 24750171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
    Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Kwong AJ; Kim WR; Flemming JA
    Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in liver transplantation for hepatitis C in a country with reduced access to direct-acting antiviral agents.
    Dirchwolf M; Marciano S; Giunta DH; Posadas-Martínez ML; Biggins SW; Ruf AE
    Clin Transplant; 2018 Apr; 32(4):e13230. PubMed ID: 29485711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965.
    Shirazi F; Wang J; Wong RJ
    J Clin Exp Hepatol; 2020; 10(1):30-36. PubMed ID: 32025164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades.
    Puigvehí M; Hashim D; Haber PK; Dinani A; Schiano TD; Asgharpour A; Kushner T; Kakked G; Tabrizian P; Schwartz M; Gurakar A; Dieterich D; Boffetta P; Friedman SL; Llovet JM; Saberi B
    Am J Transplant; 2020 Jan; 20(1):220-230. PubMed ID: 31437349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy.
    Vaziri A; Gimson A; Agarwal K; Aldersley M; Bathgate A; MacDonald D; McPherson S; Mutimer D; Gelson W
    J Viral Hepat; 2019 Feb; 26(2):231-235. PubMed ID: 30339294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
    Taniguchi M
    Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
    Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
    Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA.
    Cholankeril G; Goli K; Rana A; Hernaez R; Podboy A; Jalal P; Da BL; Satapathy SK; Kim D; Ahmed A; Goss J; Kanwal F
    Hepatology; 2021 Dec; 74(6):3316-3329. PubMed ID: 34310738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.